December 17, 2011 -- Simcere will develop a cardiovascular molecule with Bristol-Myers Squibb; China Sky One Medical and three partners will invest $36.3 million to create a stem cell company; ICON acquired a China clinical-stage CRO, BeijingWits Medical Consulting; Jilin Aodong Medicine put a hold on its $25 million Vital Therapies investment; Boehringer Ingelheim announced a $91 million expansion of its Shanghai manufacturing facility; Pfizer executives said the company has a two-fold R&D strategy for China; Sihuan Pharmaceutical broke ground on a new $110 million campus in Beijing; Quintiles will launch a new company, named Kun Tuo, to build its China presence; and China’s State Council has tightened regulation of TCM products. More details…..
Stock Symbols: (NYSE: SCR) (NYSE: BMY) (NSDQ: CSKI) (NSDQ: ICLR) (SHE: 000623) (NYSE: PFE) (HKEX: 0460)
